INS and metabolic dysfunction-associated steatotic liver disease: In the pooled analysis of the substitution trials we found no adverse effect on body weight [107], fasting lipids [108, 109], blood pressure [110], uric acid concentration [111], glycaemic control and insulin sensitivity [112, 113], postprandial lipids [114] and markers of non-alcoholic fatty liver disease (NAFLD) [115] in individuals with varying metabolic phenotypes.